With rapid scientific advancement, mounting government support, and heaps of investor cash, the Chinese biotech sector is threatening to one day compete with the U.S. But that doesn’t mean the two can’t get along.
Vivace Therapeutics, a freshly unveiled startup focused on cancer, is a picture of Sino-American cooperation. Backed by investors from both countries, the company’s foundational science comes from Chinese-born researchers trained in the U.S. And Vivace’s managers will operate out of the Bay Area while contract scientists hammer away at its lab work in China.
“We’re really leveraging the best of the U.S. and China,” said Sofie Qiao, Vivace’s CEO.
About the Author Reprints
